The 2025 National Medical Insurance Negotiations commenced in Beijing on October 30.

This year’s negotiations mark the first official introduction of the "Commercial Insurance Innovative Drug List" mechanism, building upon the existing routine adjustments to the medical insurance catalog. The new list focuses on innovative drugs that exceed basic coverage criteria and are temporarily ineligible for inclusion in the essential catalog but demonstrate high innovation, significant clinical value, and substantial patient benefits. These drugs are recommended for reference by multi-tiered medical security systems, including commercial health insurance and medical mutual aid programs.

According to an August 28 announcement by the National Healthcare Security Administration, 535 generic drug names passed the formal review for the 2025 Essential Drug List adjustment. Meanwhile, 121 generic drug names qualified for the Commercial Insurance Innovative Drug List, with 79 of them applying for both the basic medical insurance catalog and the new commercial insurance list.